Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year High - What's Next?
Day One Biopharmaceuticals (NASDAQ:DAWN) recently hit a new 52-week high of $21.47, trading with heavy volume. Despite this, analyst consensus is a "Hold" with an average target price of $23.29, and several firms have reduced their price objectives. The company reported a quarterly EPS miss but a revenue beat, and institutional ownership remains high while insiders have recently sold shares.
JonesTrading Maintains Day One Biopharmaceuticals(DAWN.US) With Hold Rating, Maintains Target Price $21.5
JonesTrading analyst Soumit Roy has reiterated a Hold rating for Day One Biopharmaceuticals (DAWN.US), maintaining a target price of $21.5. According to TipRanks data, Roy's past performance shows a 32.2% success rate and an average return of -7.2% over the last year. This information is intended for informational purposes only and not as an investment recommendation.
SG Americas Securities LLC Buys 323,747 Shares of Day One Biopharmaceuticals, Inc. $DAWN
SG Americas Securities LLC significantly increased its stake in Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) by 1,228.9% in the fourth quarter, now owning 350,092 shares valued at $3.26 million. Despite reaching a 12-month high in share price and beating revenue estimates, the company reported a net loss and continues to have negative margins and returns. Analyst sentiment for DAWN is predominantly "Hold" with a consensus price target of $23.29, alongside recent insider selling.
Hennion & Walsh Asset Management Inc. Buys 218,383 Shares of Day One Biopharmaceuticals, Inc. $DAWN
Hennion & Walsh Asset Management Inc. significantly increased its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 229.7% in the fourth quarter, now holding 313,455 shares valued at $2.92 million. This comes as institutional investors collectively own 87.95% of the company, despite recent insider selling totaling 36,461 shares worth $422,948. Day One Biopharmaceuticals reported mixed quarterly results with an EPS miss but a revenue beat, while analysts maintain a consensus "Hold" rating with a target price of $23.29.
Day One Biopharmaceuticals (Nasdaq:DAWN) - Stock Analysis
Day One Biopharmaceuticals (Nasdaq:DAWN) is a commercial-stage biopharmaceutical company with a market cap of US$2.2 billion. The stock is currently trading at US$21.42, which analysts suggest is 0.4% undervalued. Its lead product, OJEMDA (tovorafenib), is positioned for revenue growth with expanding clinical indications and European approvals, though some risks related to single-product dependency and regulatory scrutiny remain.
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Down 20.3% in March
Day One Biopharmaceuticals (NASDAQ:DAWN) experienced a 20.3% decrease in short interest in March, with the total falling to 8,091,418 shares. The company has an average "Hold" rating from Wall Street analysts with a target price of $23.29, following several recent downgrades. Insider selling by the CFO and another insider was reported, while institutional ownership remains high at 87.95%.
(DAWN) Risk Channels and Responsive Allocation
The article provides an AI-generated analysis for Day One Biopharmaceuticals Inc. (NASDAQ: DAWN), indicating a near-term neutral sentiment but mid and long-term strength. It details specific institutional trading strategies, including long, breakout, and short positions with entry zones, targets, and stop losses. The analysis also presents multi-timeframe signal strengths, support, and resistance levels for DAWN.
Are SEM, DAWN, VRE Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating Select Medical Holdings Corporation (SEM), Day One Biopharmaceuticals, Inc. (DAWN), and Veris Residential, Inc. (VRE) for potential violations of federal securities laws and breaches of fiduciary duties. The firm is concerned that the proposed sales of these companies may not offer fair deals to ordinary shareholders, as insiders could receive disproportionate financial benefits. Halper Sadeh LLC encourages shareholders to contact them to discuss their rights and options.
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN
Kahn Swick & Foti, LLC is investigating the proposed sale of Day One Biopharmaceuticals, Inc. (NasdaqGS: DAWN) to Servier for $21.50 per share in cash. The law firm is seeking to determine if this consideration and the process leading to it are adequate, or if the Company is undervalued. Shareholders who believe the transaction undervalues the company are encouraged to contact KSF.
Day One Biopharmaceuticals Executives Sell Shares Amid Legal Firm's Scrutiny of $21.50 Offer
Executives at Day One Biopharmaceuticals have sold $422,980 worth of shares, raising concerns as a law firm investigates if Servier's $21.50 per share acquisition offer undervalues the company, especially after a 123.5% stock surge. This insider selling contrasts with some institutional accumulation, like BlackRock's increased stake, but aligns with a net withdrawal of institutional ownership and hints at potential undervaluation if the deal closes.
Vanguard amends holdings for Day One Biopharmaceuticals (NASDAQ: DAWN), reports 0 shares
The Vanguard Group filed an amended Schedule 13G/A, reporting 0 shares of Day One Biopharmaceuticals Inc. (NASDAQ: DAWN), representing 0% beneficial ownership. This change is due to an internal realignment on January 12, 2026, causing Vanguard's subsidiaries and business divisions to report their holdings separately, rather than indicating a sale of shares. The filing was signed by Ashley Grim, Head of Global Fund Administration, on March 26, 2026.
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Day One Biopharmaceuticals, Inc. (NasdaqGS: DAWN) to Servier for $21.50 per share in cash. The law firm is examining whether this consideration and the process leading to the transaction are adequate and fair to shareholders. Shareholders who believe the Company is undervalued are encouraged to contact KSF for legal consultation regarding their rights.
Servier adds exhibit to Day One Biopharma tender offer (DAWN)
Servier S.A.S., Servier Pharmaceuticals LLC, and Servier Detroit Inc. (the Servier Parties) have filed an Amendment No. 1 to their Schedule TO regarding the tender offer for Day One Biopharmaceuticals (DAWN). This amendment adds an "Integration Presentation" as an exhibit to the existing tender offer statement. The core terms of the tender offer remain unchanged, with the amendment solely supplementing Item 12 (Exhibits).
Servier offers $21.50 per share for Day One (NASDAQ: DAWN) in agreed deal
Servier is offering $21.50 per share in cash to acquire Day One Biopharmaceuticals (NASDAQ: DAWN) in an agreed deal. The Offer, which started on March 26, 2026, and is set to expire on April 22, 2026, has been recommended by Day One's board of directors, who believe it provides significant and certain value to shareholders. Key conditions include a majority of shares tendered, HSR clearance, and no legal restraints, with Day One becoming a wholly-owned subsidiary of Servier upon completion.
Servier (DAWN) offers $21.50 in cash to buy Day One Biopharma shares
Servier Detroit Inc. has launched a cash tender offer to acquire all outstanding common shares of Day One Biopharmaceuticals, Inc. (DAWN) for $21.50 per share. The offer is outlined in an Offer to Purchase document dated March 26, 2026, and is a key part of a previously announced Agreement and Plan of Merger from March 6, 2026. This acquisition aims to expand Servier's portfolio in rare oncology.
GLAZER CAPITAL, LLC Acquires Significant Stake in Day One Biopharma
GLAZER CAPITAL, LLC has acquired 5,615,390 shares of Day One Biopharmaceuticals Inc (NASDAQ: DAWN) at $21.27 per share, representing 3.37% of GLAZER CAPITAL's portfolio and a 5.40% stake in Day One. This strategic investment highlights GLAZER CAPITAL's interest in the biotechnology sector and Day One's potential for growth in targeted cancer therapies, particularly for pediatric patients, despite current profitability challenges. Other notable investors, such as Ken Fisher, also show interest in Day One Biopharmaceuticals Inc.
Servier (DAWN) plans tender offer under March 6, 2026 merger agreement
Servier and its subsidiaries are planning a tender offer for all outstanding shares of Day One Biopharmaceuticals, Inc. (DAWN) following a Merger Agreement dated March 6, 2026. This announcement serves as a preliminary communication, urging shareholders to review forthcoming offer documents, including the Schedule TO and Schedule 14D-9. The transaction highlights the strategic acquisition by Servier while acknowledging typical risks associated with biopharma deals like clinical, regulatory, and integration uncertainties.
Glazer Capital (NASDAQ: DAWN) reports 5.6M-share, 5.44% stake
Glazer Capital, LLC and Paul J. Glazer have reported a beneficial ownership of 5,615,390 shares, representing a 5.44% stake in Day One Biopharmaceuticals (NASDAQ: DAWN). This disclosure was made via a Schedule 13G filing, indicating a passive investment intent. The shares are held by funds managed by Glazer Capital, with Glazer Capital Enhanced Master Fund, Ltd. having the right to receive proceeds from the sale of more than 5% of the outstanding common stock.
Day One Biopharmaceuticals reiterates $225M–$250M OJEMDA revenue target as pipeline expands with Emi-Le integration
Day One Biopharmaceuticals is reiterating its 2024 revenue guidance for OJEMDA, projecting $225 million to $250 million. This comes as the company focuses on expanding its pipeline through the integration of Emi-Le, a drug developed in collaboration with Ascentage Pharma for pediatric patients with high-grade glioma. The company also anticipates filing a New Drug Application for vorasidenib in frontline diffuse low-grade glioma by the end of 2024.
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Hold" from Brokerages
Day One Biopharmaceuticals (NASDAQ:DAWN) has received a consensus "Hold" rating from brokerages, with an average one-year target price of $23.75. Recent analyst adjustments have seen several firms reiterating "neutral" ratings and lowering target prices, while Zacks Research and JonesTrading downgraded the stock to "hold." The company recently reported earnings, missing EPS estimates but exceeding revenue expectations, and institutional investors have been actively adjusting their holdings in DAWN.
(DAWN) Movement as an Input in Quant Signal Sets
This article analyzes Day One Biopharmaceuticals Inc. (NASDAQ: DAWN) using quantitative AI models. It indicates a near-term neutral sentiment but mid-to-long-term strength, with identified support and resistance levels. The report also outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, alongside multi-timeframe signal analysis.
Mak Capital One LLC Invests $10.21 Million in Day One Biopharmaceuticals, Inc. $DAWN
Mak Capital One LLC has invested $10.21 million in Day One Biopharmaceuticals (NASDAQ:DAWN), acquiring a 1.41% stake in the company. Other hedge funds also significantly increased their positions in DAWN, bringing institutional ownership to 87.95%. Despite trading near its 52-week high, Day One Biopharmaceuticals reported negative earnings and margins, and analysts maintain a "Hold" rating with a $23.75 price target.
Day One Biopharmaceuticals (NasdaqGS:DAWN) Stock Forecast & Analyst Predictions
This article provides an analyst prediction and stock forecast for Day One Biopharmaceuticals (NasdaqGS:DAWN). Analysts anticipate significant growth, with earnings and revenue projected to increase by 65.7% and 24.8% annually, respectively, and EPS by 65.2% annually. The company is expected to become profitable within the next three years, outpacing the US market growth.
DAWN stock jumps 66% on $2.5B buyout offer from Servier
This article reports that Dawn stock surged by 66% following a $2.5 billion buyout offer from Servier. The content of the article itself is missing, therefore, further details of the deal are unavailable.
Servier All Cash Deal Reframes Day One Biopharmaceuticals Valuation Story
Servier Pharmaceuticals has agreed to acquire Day One Biopharmaceuticals (NasdaqGS:DAWN) in an all-cash transaction, changing the company's valuation story from standalone growth to a focus on deal terms. The acquisition highlights current valuations for late-stage oncology assets in cash transactions. This move shifts investor attention to regulatory approvals, closing conditions, and how the purchase price compares to fair value estimates.
Servier Acquires Day One Biopharmaceuticals for $2.5B, Betting on Tovorafenib and the Pediatric Glioma Frontier
Servier has acquired Day One Biopharmaceuticals for $2.5 billion, primarily for its key asset, Ojemda (tovorafenib), a recently approved treatment for pediatric low-grade glioma. This acquisition strengthens Servier's rare oncology portfolio, especially in glioma, complementing its prior acquisition of Agios Pharmaceuticals. The deal also includes Day One's pipeline of antibody-drug conjugates, strategically positioning Servier in the growing pediatric oncology market.
Servier All Cash Deal Reframes Day One Biopharmaceuticals Valuation Story
Servier Pharmaceuticals has announced an all-cash agreement to acquire Day One Biopharmaceuticals (NasdaqGS:DAWN), fundamentally changing the company's valuation perspective. This acquisition integrates Day One Biopharmaceuticals, specializing in oncology therapies, into Servier, and shifts investor focus to the deal terms, timeline, and closing conditions. The transaction also provides a new reference point for valuing late-stage oncology assets in cash deals within the biotech sector.
Are DAWN, TALK, UNF Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating Day One Biopharmaceuticals (DAWN), Talkspace Inc. (TALK), and UniFirst Corporation (UNF) regarding their proposed sales. The firm is concerned that insiders may receive substantial financial benefits not available to ordinary shareholders and that the transactions might limit superior competing offers. Shareholders are encouraged to contact Halper Sadeh LLC to discuss their rights.
Servier All Cash Deal Reframes Day One Biopharmaceuticals Valuation Story
Servier Pharmaceuticals has agreed to acquire Day One Biopharmaceuticals (NasdaqGS:DAWN) in an all-cash transaction. This deal shifts focus for Day One investors to deal terms and adds a new reference point for valuing late-stage oncology assets. Simply Wall St indicates that DAWN shares are currently trading near analyst targets but significantly below its internal fair value estimate.
Day One Biopharmaceuticals (NASDAQ:DAWN) Given "Neutral" Rating at JPMorgan Chase & Co.
JPMorgan Chase & Co. has reissued a "Neutral" rating for Day One Biopharmaceuticals (DAWN) and lowered its price target to $21.50 from $27.00. This revision reflects a trend among several analysts, resulting in an average "Hold" rating and a price target of $23.75 for the stock. The company faces challenges including missed Q4 EPS estimates, negative margins, insider stock sales, and its status as a clinical-stage biotech.
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio
Servier is set to acquire Day One Biopharmaceuticals for approximately $2.5 billion, at $21.50 per share in cash, a premium of about 68% over Day One's closing price on March 5, 2026. This acquisition will strengthen Servier's oncology portfolio, especially in rare cancers and pediatric low-grade glioma, and aligns with its 2030 ambition in oncology. The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions including shareholder tender and antitrust clearance.
Day One Biopharmaceuticals' (DAWN) "Neutral" Rating Reiterated at HC Wainwright
HC Wainwright reiterated a "Neutral" rating for Day One Biopharmaceuticals (NASDAQ:DAWN) with a slightly reduced price target of $21.50, following Servier's acquisition agreement for $2.5 billion, or $21.50 per share. This acquisition has led to a significant pre-market surge in DAWN's stock but also prompted several brokers to cut their ratings to "Hold" due to the stock trading near the offer price. The company recently missed EPS estimates but beat revenue expectations, and insider selling has been observed.
Wedbush Reaffirms Neutral Rating for Day One Biopharmaceuticals (NASDAQ:DAWN)
Wedbush has reaffirmed a "neutral" rating for Day One Biopharmaceuticals (NASDAQ:DAWN) but lowered its price target to $21.50 from $30.00, implying a minimal upside. Analyst coverage for DAWN is largely mixed with a "Hold" consensus, and the company recently reported a Q4 EPS loss while beating revenue estimates. Insiders have been net sellers of the stock, further highlighting a cautious sentiment.
Day One Biopharmaceuticals, Inc. Buyout: Why Servier’s $2.5 Billion Ojemda Deal Matters Now
Servier is acquiring Day One Biopharmaceuticals for $2.5 billion, driven by the strategic importance of Ojemda, Day One's U.S.-approved pediatric low-grade glioma treatment. The deal, supported by Day One's board, values the company at $21.50 per share, representing a 68% premium. While Day One's Ojemda sales were $155.4 million in 2025 with strong 2026 projections, the acquisition still requires shareholder participation and U.S. antitrust approval.
Day One (DAWN) Climbs to 3-Year High on $2.5-Billion Merger
Day One Biopharmaceuticals Inc. (DAWN) saw its stock price climb to a three-year high following the announcement of a $2.5 billion merger with France-based Servier. Servier will acquire Day One's shares at $21.50 apiece, representing a 68 percent premium. The acquisition is expected to close in the second quarter of the year.
Servier Acquiring Day One Biopharmaceuticals For About $2.5 Billion
Servier, an independent international pharmaceutical group, announced its definitive agreement to acquire Day One Biopharmaceuticals for approximately $2.5 billion. This acquisition aims to strengthen Servier’s position and expand its rare oncology portfolio, offering a significant premium of about 68% over Day One’s recent closing share price. The transaction is expected to close in the second quarter of 2026, pending regulatory approvals, and will be funded by Servier's existing cash and investments.
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Day One Biopharmaceuticals, Inc. (NasdaqGS: DAWN) to Servier for $21.50 per share in cash. KSF is examining whether this price and the process leading to it are adequate, or if the consideration undervalues the company. Shareholders are encouraged to contact KSF if they believe the transaction undervalues the company or wish to discuss their legal rights.
Servier to Buy Day One for $2.5 Billion, Expanding Oncology Portfolio
Servier is set to acquire Day One Biopharmaceuticals for $2.5 billion, aiming to significantly expand its oncology portfolio, particularly in rare cancers. The acquisition price of $21.50 per share represents a substantial premium of 68% over Day One’s closing price. This strategic move is expected to position Servier as a leader in pediatric low-grade glioma research and treatment.
Servier to acquire Day One, maker of pediatric cancer drug, for $2.5B
French pharmaceutical company Servier announced its plan to acquire Day One Biopharmaceuticals for approximately $2.5 billion. The deal values Day One shares at $21.50 each, a significant premium. The acquisition is centered around Day One's drug Ojemda, which received U.S. approval in 2024 for treating pediatric low-grade glioma, a common form of childhood brain cancer, and will expand Servier's rare cancer pipeline.
Servier to Acquire Day One Biopharmaceuticals in Merger
Servier Pharmaceuticals LLC has agreed to acquire Day One Biopharmaceuticals (DAWN) for $21.50 per share in cash, valuing the biotech at approximately $2.5 billion. This all-cash tender offer represents a significant premium for Day One shareholders and aims to bolster Servier's presence in the rare oncology and pediatric cancer treatment markets. The deal is expected to strengthen Servier's pipeline, particularly in pediatric low-grade glioma.
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio
Servier announced its definitive agreement to acquire Day One Biopharmaceuticals for $21.50 per share in cash, totaling approximately $2.5 billion. This acquisition will strengthen Servier's position in rare oncology and expand its pipeline with programs targeting various cancers, positioning it as a leader in pediatric low-grade glioma. The transaction is expected to close in the second quarter of 2026.
This Biopharma Company Is Being Bought for $2.5 Billion. Its Stock Is Up 66%.
Day One Biopharmaceuticals, a company specializing in pediatric cancer treatments, is being acquired by French drugmaker Servier for $2.5 billion. The all-cash deal values Day One Biopharmaceuticals at $21.50 per share, causing its stock to jump by 66%. This acquisition highlights the value of companies focused on niche medical areas like pediatric oncology.
Day One Biopharmaceuticals: 'Strong Buy,' Several 2026 Milestones In Play Plus OJEMDA Growth
Day One Biopharmaceuticals (DAWN) maintains a "Strong Buy" rating due to its robust pipeline, multiple catalysts, and significant OJEMDA revenue growth. The company anticipates key clinical data readouts for two novel ADC programs in mid- and late 2026, alongside ongoing label expansion efforts for OJEMDA. Strong cash reserves and potential takeover speculation further enhance its strategic outlook.
Day One Biopharmaceuticals Is Being Bought for $2.5 Billion. Its Stock Is Jumping.
Day One Biopharmaceuticals' stock surged on Friday after French drugmaker Servier announced an all-cash acquisition of the company for $21.50 per share. The deal values Day One Biopharmaceuticals, which specializes in pediatric cancer treatments, at $2.5 billion.
Servier Adds to Childhood Brain Tumor Portfolio With $2.5B Day One Buy
France's Servier is acquiring Day One Biopharmaceuticals for $2.5 billion, aiming to expand its oncology portfolio, particularly in areas of high unmet need. The acquisition includes Ojemda, an FDA-approved drug for pediatric glioma that generated $155.4 million in sales in 2025. This deal supports Servier's 2030 goal to target difficult-to-treat cancers and builds on Day One's mission to address treatment gaps for both adult and pediatric cancer patients.
Day One Biopharmaceuticals Stock Surges 65% Over Acquisition Deal With Servier
Day One Biopharmaceuticals (DAWN) stock surged by approximately 65% after Servier announced an agreement to acquire the company for $21.50 per share in cash. The deal, expected to close in the second quarter of 2026, offers Day One a significant opportunity to expand its scientific reach and primary program in pediatric low-grade glioma. Shares opened at $21.12 and reached $21.19, reflecting strong investor confidence in the acquisition.
Shareholder Alert: The Ademi Firm investigates whether Day One Biopharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders
Ademi LLP is investigating Day One Biopharmaceuticals (NASDAQ: DAWN) for potential breaches of fiduciary duty related to its recently announced acquisition by Servier. Shareholders are set to receive $21.50 per share in cash, totaling approximately $2.5 billion, but the firm is examining whether this constitutes a fair price, especially considering the substantial benefits for Day One insiders and a significant penalty imposed on competing bids. Ademi LLP encourages affected shareholders to join their investigation to ensure the board of directors fulfilled its duties to all shareholders.
Day One Biopharmaceuticals Inc Co To Pay Servier Pharmaceuticals Termination Fee Of $87.7 Million If Deal Is Terminated Under Certain Circumstances
Day One Biopharmaceuticals Inc. will pay Servier Pharmaceuticals a termination fee of $87.7 million if a deal between the two companies is terminated under specific conditions. This brief report, sourced from Reuters via Refinitiv, pertains to mergers and acquisitions activity involving DAWN.
Servier pays 68% premium in $2.5B deal for Day One’s pediatric cancer drugs
Servier is set to acquire Day One Biopharmaceuticals for approximately $2.5 billion, offering $21.50 per share in cash, which represents a 68% premium over Day One's closing price on March 5, 2026. This acquisition will expand Servier's rare oncology pipeline, particularly strengthening its position in pediatric low-grade glioma treatments. The transaction is expected to close in Q2 2026, contingent on a majority tender of Day One shares and U.S. antitrust clearance, and will be funded through Servier's existing cash and investments.
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio
Servier is set to acquire Day One Biopharmaceuticals for approximately $2.5 billion, at $21.50 per share in cash. This acquisition aims to strengthen Servier’s position in rare oncology, particularly in pediatric low-grade glioma, and expand its pipeline of targeted therapies for both adult and pediatric cancers. The transaction is expected to close in the second quarter of 2026, advancing Servier's 2030 ambition to develop innovative treatments for patients with high unmet medical needs.
